چكيده لاتين :
Background: Various responses and different prognosis to specific treatment in different patients from one hand , and
importance of IFN-y produ cer cells on the other hand impressed us to study Tcl. Methods: The stud y was conducted in
Ghaem Medical Center and Bu-Ali Research Institute, Mashhad Univ ersity of Medical Scien ces, Iran from 2001 to 2002 .
Lymphocytes of 36 patients were counted and cultured . Percentage of different respon sible immunity cells in 29 patients,
were determined by Flow Cytom etry System before and after medication with gJucantim e (IM) . Patients who showed
improvement after the tre atment were put into group I and those who did not recover were labeled group 2. In this self-control
clinical trial , sampling method was consecutive non-probability and the results were analyzed by t-test consequently.
Results: The percentage of Tc I cells showed a significant incre ase despite of being stimulated with Phorpol-Mristate-Acetate
ePMA) amon g the whole studied patients and group I (P= 0.069 and P= 0.040 , respectively). While no significant
change was observed amon g patients in group 2. Conclusion: This verifies the influen ce of Tc I cells for the treatment of
patients with CL and perh aps the role of glucantime in improving the cell immunity response through increa sing such cells.
